Combined PSMA PET and mpMRI could enable biopsy-free prostate cancer diagnosis

A study in JNM suggests combining 18F-flotufolastat PSMA PET with multiparametric MRI may allow biopsy-free diagnosis of prostate cancer. Specific accuracy metrics and study design were not provided in this announcement.

• Primary source is a Journal of Nuclear Medicine study.
• Claim: dual-imaging approach may replace biopsy, but no performance numbers or patient cohort details are available from the snippet.
• Unverified: cannot confirm design, sample size, or validation.

Announcement only; primary study not reviewed and no performance data provided in the snippet.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.